Disruption of the hypothalamic-pituitary-adrenal axis may occur after aneurysmal subarachnoid hemorrhage, resulting in hypopituitarism. An electronic literature search was conducted to identify articles with English-language abstracts published between 1980 and March 2011 that addressed hypothalamic-pituitary-adrenal axis insufficiency and hormone replacement. A total of 18 observational and prospective, randomized studies were selected for this review. Limited data are available evaluating pituitary effects during the acute stage after subarachnoid hemorrhage, with inconsistent results reported. Overall, acutely after subarachnoid hemorrhage, cortisol levels may initially be supranormal, decreasing toward normal levels over time. During the months to years after subarachnoid hemorrhage, pituitary deficiency may occur in up to one in three patients. Limited data suggest modest outcome benefits with fludrocortisone and no benefit or harm from corticosteroids. © Springer Science+Business Media, LLC 2011.

Vespa, P., Citerio, G. (2011). SAH pituitary adrenal dysfunction. NEUROCRITICAL CARE, 15(2), 365-368 [10.1007/s12028-011-9595-7].

SAH pituitary adrenal dysfunction

CITERIO, GIUSEPPE
2011

Abstract

Disruption of the hypothalamic-pituitary-adrenal axis may occur after aneurysmal subarachnoid hemorrhage, resulting in hypopituitarism. An electronic literature search was conducted to identify articles with English-language abstracts published between 1980 and March 2011 that addressed hypothalamic-pituitary-adrenal axis insufficiency and hormone replacement. A total of 18 observational and prospective, randomized studies were selected for this review. Limited data are available evaluating pituitary effects during the acute stage after subarachnoid hemorrhage, with inconsistent results reported. Overall, acutely after subarachnoid hemorrhage, cortisol levels may initially be supranormal, decreasing toward normal levels over time. During the months to years after subarachnoid hemorrhage, pituitary deficiency may occur in up to one in three patients. Limited data suggest modest outcome benefits with fludrocortisone and no benefit or harm from corticosteroids. © Springer Science+Business Media, LLC 2011.
Articolo in rivista - Articolo scientifico
Adrenal insufficiency; Adrenocorticotropic hormone; Cortisol; Growth hormone; Hypothalamic; Abdomen, Acute; Adrenal Insufficiency; Critical Care; Humans; Hypopituitarism; Subarachnoid Hemorrhage; Neurology (clinical); Critical Care and Intensive Care Medicine
English
2011
15
2
365
368
reserved
Vespa, P., Citerio, G. (2011). SAH pituitary adrenal dysfunction. NEUROCRITICAL CARE, 15(2), 365-368 [10.1007/s12028-011-9595-7].
File in questo prodotto:
File Dimensione Formato  
Neurocrit Care 2011 Vespa-1.pdf

Solo gestori archivio

Dimensione 159.21 kB
Formato Adobe PDF
159.21 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/54859
Citazioni
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
Social impact